'Atorvastatin' diaporamas de présentation

F. U. Afifi , E. Hallaq, V. Kasabri and S. Litescu

Antidiabetic and antiobesity potential of Adiantum capillus-veneris used in the traditional medicine of Jordan. F. U. Afifi , E. Hallaq, V. Kasabri and S. Litescu School of Pharmacy, University of Jordan, Amman-Jordan Natural Products 2016, Melbourne, Australia - July 25-27 th , 2016.

523 views • 52 slides

638 views • 48 slides

Prevention of Periop MI: Where are we now; & where are we going?

Prevention of Periop MI: Where are we now; & where are we going?. H Yang Department of Anesthesiology. Pre-op. Intra-. Post-. n. (%). op (%). op (%). Mangano. 474. 20. 25. 40. NEJM. 1990. Raby. 115. 20. 18. 30. JAMA. 1992. Perioperative Ischemia.

494 views • 40 slides

Heart Failure

790 views • 33 slides

A struggle to breathe

A struggle to breathe. Dr Hardy Firm: Verena Walsh, Sofia Thorell , Caroline Sargeant , Patrick Birch, Helen Thornton, Hitesh Khanna , Alex Lomax & Michael Shipton. Case Presentation.

482 views • 31 slides

Atorvastatin Rosuvastatin Potency

Atorvastatin Rosuvastatin Potency.

325 views • 31 slides

Atorvastatin: Effective Therapy for a Broad Range of Dyslipidemias

Atorvastatin: Effective Therapy for a Broad Range of Dyslipidemias. For individuals with:. Trial of dietary therapy and counselling:. Initiate drug therapy if LDL-C remains:. LDL-C Goal:. No CHD and <2 CHD risk factors. 6-12 months. > 190 mg/dL > 4.9 mmol/L. <160 mg/dL <4.1 mmol/L.

278 views • 27 slides

What Is Atorvastatin Generic For

What Is Atorvastatin Generic For.

175 views • 17 slides

Atorvastatin Impurity

282 views • 12 slides

Atorvastatin Impurity | Atorvastatin Epoxy Tetrahydrofuran Analog

Atorvastatin is used to reduce the levels of bad cholesterol and triglycerides in the blood. Here are some of the products of Atorvastatin which are widely used in the pharma industry like Atorvastatin Epoxy Tetrahydrofuran Analog, Atorvastatin FX1 Impurity, Atorvastatin FXA Impurity, & Atorvastatin Pyrrolidone Phenanthrene Calcium

145 views • 12 slides

Collaborative Atorvastatin Diabetes Study (CARDS)

372 views • 8 slides

Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96

Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96. Baseline Characteristics of the 2342 Study Subjects. Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96.

204 views • 7 slides

Recent statin trials: Reduction in primary outcome in patients with diabetes. HPS. Steno-2. 0. 10. 22. 20. Relative risk reduction (%). P < 0.0001. 30. 40. 53. 50. P = 0.007. 60. HPS: major coronary event, stroke, or revascularization

255 views • 6 slides

III. TECHNOLOGY MILESTONES IN HEALTH AND MEDICINE

III. TECHNOLOGY MILESTONES IN HEALTH AND MEDICINE. III.6. Anti-infective Drugs. Salvarsan and Prontosil

129 views • 2 slides

Change in eGFR with atorvastatin or placebo in participants with CKD

Change in eGFR with atorvastatin or placebo in participants with CKD. 6. Atorvastatin. Placebo. 4. Least squares mean change in eGFR (mlL/min/1.73m 2. 2. 0. -2. baseline. 48. 60. 12. 24. 36. Study visit (months). Amarenco et al., Stroke 2014.

122 views • 2 slides

Change in inflammatory activity after statin use in patients with active periodontitis

*. *. 0.5 0 -0.5 -1. Change in inflammatory activity after statin use in patients with active periodontitis. Atorvastatin 10 Atorvastatin 80. **. **. Change in periodontal FDG uptake ? TBR. 12 Weeks after randomisation.

128 views • 1 slides

MICROWAVE SYNTHESIS OF ATORVASTATIN CALCIUM SALT

176 views • 1 slides

Roth EM et al. N Engl J Med 2012.DOI : 10.1056/NEJMoa1201832

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia Mean Percent Change from Baseline in LDL-c Level. Roth EM et al. N Engl J Med 2012.DOI : 10.1056/NEJMoa1201832.

121 views • 1 slides